Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Klebanoff Website

Christopher A. Klebanoff, M.D.

Selected Publications

1)  Roychoudhuri R, Hirahara K, Mousavi K, Clever D, Klebanoff CA, Bonelli M, Sciumè G, Zare H, Vahedi G, Dema B, Yu Z, Liu H, Takahashi H, Rao M, Muranski P, Crompton JG, Punkosdy G, Bedognetti D, Wang E, Hoffmann V, Rivera J, Marincola FM, Nakamura A, Sartorelli V, Kanno Y, Gattinoni L, Muto A, Igarashi K, O'Shea JJ, Restifo NP.
BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis.
Nature. 498: 506-10, 2013.
2)  Sukumar M, Liu J, Ji Y, Subramanian M, Crompton JG, Yu Z, Roychoudhuri R, Palmer DC, Muranski P, Karoly ED, Mohney RP, Klebanoff CA, Lal A, Finkel T, Restifo NP, Gattinoni L.
Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function.
J. Clin. Invest. 123: 4479-88, 2013.
3)  Klebanoff CA, Spencer SP, Torabi-Parizi P, Grainger JR, Roychoudhuri R, Ji Y, Sukumar M, Muranski P, Scott CD, Hall JA, Ferreyra GA, Leonardi AJ, Borman ZA, Wang J, Palmer DC, Wilhelm C, Cai R, Sun J, Napoli JL, Danner RL, Gattinoni L, Belkaid Y, Restifo NP.
Retinoic acid controls the homeostasis of pre-cDC-derived splenic and intestinal dendritic cells.
J. Exp. Med. 2013.
4)  Gattinoni L, Klebanoff CA, Restifo NP.
Paths to stemness: building the ultimate antitumour T cell.
Nat. Rev. Cancer. 12: 671-84, 2012.
5)  Klebanoff CA, Gattinoni L, Restifo NP.
Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?.
J. Immunother. 35: 651-60, 2012.
6)  Klebanoff CA, Gattinoni L.
Stubborn Tregs limit T-cell therapy.
Blood. 120: 2352-4, 2012.
7)  Klebanoff CA, Gattinoni L, Palmer DC, Muranski P, Ji Y, Hinrichs CS, Borman ZA, Kerkar SP, Scott CD, Finkelstein SE, Rosenberg SA, Restifo NP.
Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice.
Clin. Cancer Res. 17: 5343-52, 2011.
8)  Ji Y, Pos Z, Rao M, Klebanoff CA, Yu Z, Sukumar M, Reger RN, Palmer DC, Borman ZA, Muranski P, Wang E, Schrump DS, Marincola FM, Restifo NP, Gattinoni L.
Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits the formation of memory CD8+ T cells.
Nat. Immunol. 12: 1230-7, 2011.
9)  Muranski P, Borman ZA, Kerkar SP, Klebanoff CA, Ji Y, Sanchez-Perez L, Sukumar M, Reger RN, Yu Z, Kern SJ, Roychoudhuri R, Ferreyra GA, Shen W, Durum SK, Feigenbaum L, Palmer DC, Antony PA, Chan CC, Laurence A, Danner RL, Gattinoni L, Restifo NP.
Th17 cells are long lived and retain a stem cell-like molecular signature.
Immunity. 35: 972-85, 2011.
10)  Klebanoff CA, Acquavella N, Yu Z, Restifo NP.
Therapeutic cancer vaccines: are we there yet?.
Immunol. Rev. 239: 27-44, 2011.
11)  Klebanoff CA, Yu Z, Hwang LN, Palmer DC, Gattinoni L, Restifo NP.
Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination.
Blood. 114: 1776-83, 2009.
12)  Klebanoff CA, Gattinoni L, Restifo NP.
CD8+ T-cell memory in tumor immunology and immunotherapy.
Immunol. Rev. 211: 214-24, 2006.
13)  Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, Yu Z, Finkelstein SE, Theoret MR, Rosenberg SA, Restifo NP.
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells.
J. Clin. Invest. 115: 1616-26, 2005.
14)  Klebanoff CA, Gattinoni L, Torabi-Parizi P, Kerstann K, Cardones AR, Finkelstein SE, Palmer DC, Antony PA, Hwang ST, Rosenberg SA, Waldmann TA, Restifo NP.
Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells.
Proc. Natl. Acad. Sci. U.S.A. 102: 9571-6, 2005.
15)  Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, Spiess PJ, Hwang LN, Yu Z, Wrzesinski C, Heimann DM, Surh CD, Rosenberg SA, Restifo NP.
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells.
J. Exp. Med. 202: 907-12, 2005.
16)  Klebanoff CA, Khong HT, Antony PA, Palmer DC, Restifo NP.
Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy.
Trends Immunol. 26: 111-7, 2005.
17)  Klebanoff CA, Finkelstein SE, Surman DR, Lichtman MK, Gattinoni L, Theoret MR, Grewal N, Spiess PJ, Antony PA, Palmer DC, Tagaya Y, Rosenberg SA, Waldmann TA, Restifo NP.
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells.
Proc. Natl. Acad. Sci. U.S.A. 101: 1969-74, 2004.
18)  Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA, Dellemijn TA, Antony PA, Spiess PJ, Palmer DC, Heimann DM, Klebanoff CA, Yu Z, Hwang LN, Feigenbaum L, Kruisbeek AM, Rosenberg SA, Restifo NP.
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.
J. Exp. Med. 198: 569-80, 2003.
Click Here to View Collapsed Bibliography.

This page was last updated on 10/18/2013.